Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo Expanded indication marks second disease for...

An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative Exton, Pennsylvania, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Since launching in May 2022, Sanofi/Regeneron’s Dupixent has been well received by gastroenterologists and allergists as an advancement for...

New Study on the Current State of Health Care for Eosinophilic Esophagitis Washington, D.C., May 18, 2023 (GLOBE NEWSWIRE) -- A groundbreaking report reveals challenges and barriers to timely diagnosis and effective treatment and management of a rare, but increasing...

Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...

EsoCap announces first patient enrolled in Phase II eosinophilic esophagitis trial Randomized, placebo-controlled, double-blind Phase II trial to treat 42 patients ongoing in four European countries with ESO-101ESO-101, EsoCap’s lead product candidate, consists of a capsule with a...